Ernexa Therapeutics (ERNA) Stock Price, News & Analysis

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.04 to $2.23
• 50-Day Range: $2.11 to $5.03
• 52-Week Range: $2.01 to $71.50
• Volume: 24,526 shs
• Average Volume: 689,480 shs
• Market Capitalization: $3.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

Ernexa Therapeutics Stock Analysis - MarketRank™

Ernexa Therapeutics scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Ernexa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Ernexa Therapeutics has a consensus price target of $30.00, representing about 1,335.4% upside from its current price of $2.09.

Amount of Analyst Coverage

Ernexa Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ernexa Therapeutics are expected to grow in the coming year, from ($18.02) to ($1.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ernexa Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ernexa Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ernexa Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.22% of the float of Ernexa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ernexa Therapeutics has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ernexa Therapeutics has recently increased by 37.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ernexa Therapeutics does not currently pay a dividend.

Dividend Growth

Ernexa Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Ernexa Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Ernexa Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for ERNA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.53% of the stock of Ernexa Therapeutics is held by insiders.

Percentage Held by Institutions

70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ERNA
• CIK: 748592
• Web: www.ernexatx.com
• Phone: (617) 798-6700
• Fax: 760-438-3505
• Employees: 5
• Year Founded: 1953

Price Target and Rating

• Average Price Target for Ernexa Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +1,335.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -305.93%
• Return on Assets: -169.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.01
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.64 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 1,632,000
• Free Float: 1,623,000
• Market Cap: $3.41 million
• Optionable: No Data
• Beta: 2.63